Discussion about this post

User's avatar
Andrew Stevens's avatar

Something is clearly wrong if pharma companies need prizes to motivate themselves into innovation. The market should provide all the invective necessary in terms of money, prestige and lives improved/saved. If that's not happening then it has either become so hard to bring a new drug to market that it's just not worth it, OR the company is so big that the potential of a new drug is too small for such a large company to consider--or both. In the first case restrictions needs to be eased. In the second case (and under the free market conditions) a new company with a smaller balance sheet can take advantage of the opportunity the larger company had turned down.

Expand full comment
2 more comments...

No posts